ReviewJournal of hypertension2018
Effect of antihypertensive treatment on 24-h blood pressure variability: pooled individual data analysis of ambulatory blood pressure monitoring studies based on olmesartan mono or combination treatment.
Review in Journal of hypertension, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Reducing blood pressure variability-results from a single-arm proof of concept prospective trial.Scientific reports · 2025Trial
- Effect of angiotensin II receptor blocker and salt supplementation on short-term blood pressure variability in type 2 diabetes.Journal of human hypertension · 2020Trial
- Nebivolol reduces short-term blood pressure variability more potently than irbesartan in patients with intradialytic hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2019Trial
- Asian expert consensus on high-quality hypertension management.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Review
- Consensus on the management of hypertension in individuals with diabetes by Asian-Pacific Society of hypertension (APSH) & Diabetes Asia Study Group (DASG).Journal of human hypertension · 2026Article
- Research progress on the correlation between blood pressure variability and hypertensive microvascular disease.Frontiers in cardiovascular medicine · 2026Review
- Blood Pressure Variability (BPV): What Clinicians Need to Know a 2025 Expert Consensus Report Endorsed by the Egyptian Society of Cardiology.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2025Article
- Atlas of multilineage stem cell differentiation reveals TMEM88 as a developmental regulator of blood pressure.Nature communications · 2025Article
- Exploring the link between blood pressure variability and atrial fibrillation: current insights and future directions.Journal of human hypertension · 2024Review
- Year-by-Year Blood Pressure Variability From Midlife to Death and Lifetime Dementia Risk.JAMA network open · 2023Article
- Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials.Journal of the American Heart Association · 2023Article
- Single-Pill Combination with Three Antihypertensive Agents to Improve Blood Pressure Control in Hypertension: Focus on Olmesartan-Based Combinations.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2023Review
- Clinical characteristics of two groups commonly referred to an Irish hypertension service-patients with resistant hypertension and young adults with hypertension.Irish journal of medical science · 2022Article
- Twenty-Five-Year Changes in Office and Ambulatory Blood Pressure: Results From the Coronary Artery Risk Development in Young Adults (CARDIA) Study.American journal of hypertension · 2021Article
- Change in Blood Pressure Variability Among Treated Elderly Hypertensive Patients and Its Association With Mortality.Journal of the American Heart Association · 2019Article
- Blood Pressure Variability and Therapeutic Implications in Hypertension and Cardiovascular Diseases.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2019Review
- Management of arterial hypertension with angiotensin receptor blockers: Current evidence and the role of olmesartan.Cardiovascular therapeutics · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the impact of olmesartan alone or combined with one to three antihypertensive drugs on 24-h blood pressure variability (BPV) and on distribution of BP reduction in a pooled individual data analysis of 10 double-blind, randomized, ambulatory BP monitoring (ABPM) studies.
methodsABPMs were performed before and after 6-12 weeks of treatment with placebo (n = 119), active control monotherapy [n = 1195, angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), dihydropyridine calcium channel blockers (DCCBs)] olmesartan monotherapy (n = 1410), active control dual combination [n = 79, DCCB + thiazide diuretic (TD)], olmesartan dual combination (n = 637, DCCB or TD), and triple combination therapy (n = 102, DCCB+TD). 24-h BPV was calculated as unweighted or weighted SD of the mean BP, and average real variability. BP control was assessed by smoothness index and treatment-on-variability index.
resultsThe greatest effect on 24-h systolic BPV/diastolic BPV was observed under olmesartan triple [-2.6/-1.9; -1.9/-1.3; -1.4/-1.3 mmHg] and active control dual combination [-1.8/-1.4; -1.9/-1.5; -1.2/-1.1 mmHg]. Smoothness indexes and treatment-on-variability indexes were significantly (P = 0.0001) higher under olmesartan dual (1.53/1.22, 1.67/1.29, 2.05/1.59), olmesartan triple (2.47/1.85, 2.80/2.06, 3.64/2.67), or active control dual combination (1.70/1.26, 1.85/1.33, 2.29/1.65) than under monotherapies (control: 0.86/0.73, 0.80/0.65, 1.01/0.82; olmesartan: 1.02/0.86, 0.95/0.78, 1.23/1.00). They were also greater in patients receiving high-dose olmesartan monotherapy or high-dose olmesartan dual combination than in the corresponding low-dose group.
conclusionOlmesartan plus a DCCB and/or a TD produces a larger, more sustained, and smoother BP reduction than placebo and monotherapies, a desirable feature for a more effective prevention of the cardiovascular consequences of uncontrolled hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.